Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
出版年份 2009 全文链接
标题
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 19, Issue 1, Pages 133-140
出版商
Informa Healthcare
发表日期
2009-12-01
DOI
10.1517/13543780903463862
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats
- (2009) Silke Retlich et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats
- (2009) Holger Fuchs et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice
- (2009) Dirk Reinhold et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
- (2009) E. U. Graefe-Mody et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
- (2009) T. Heise et al. DIABETES OBESITY & METABOLISM
- Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
- (2009) Holger Fuchs et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo
- (2009) Yoshiharu Horie et al. Trials
- Seprase: An overview of an important matrix serine protease
- (2008) Pamela O'Brien et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors
- (2008) Matthias Eckhardt et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
- (2008) H. He et al. DRUG METABOLISM AND DISPOSITION
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
- (2008) S. Hüttner et al. JOURNAL OF CLINICAL PHARMACOLOGY
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The incretin system and its role in type 2 diabetes mellitus
- (2008) J HOLST et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now